Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR 1,880.00
-5.00 (-0.27%)
Nov 13, 2026, 3:28 PM IST
NSE:SUNPHARMA Stock Forecast
Stock Price Forecast
According to 34 analysts polled by S&P Global, NSE:SUNPHARMA stock has a consensus rating of "Buy" and an average price target of ₹2,112. The average 1-year stock price forecast is 12.34% higher than the current stock price, while the lowest is ₹1,770 (-5.85%) and the highest is ₹2,320 (+23.40%).
Price Target: ₹2,112 (+12.34%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for NSE:SUNPHARMA stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 20 | 20 | 19 | 18 | 18 | 19 |
| Buy | 10 | 10 | 10 | 10 | 10 | 10 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 2 | 2 | 3 | 3 | 3 | 3 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 34 | 34 | 34 | 33 | 33 | 34 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst ICICI Securities No rating | ICICI Securities | Hold Maintains ₹1,980 | Hold | Maintains | ₹1,980 | +5.32% | Nov 2, 2026 |
Unknown Analyst Geojit Research No rating | Geojit Research | Buy Maintains ₹2,070 | Buy | Maintains | ₹2,070 | +10.11% | Sep 22, 2026 |
Financial Forecast
Revenue This Year
651.00B
from 584.62B
Increased by 11.35%
Revenue Next Year
722.45B
from 651.00B
Increased by 10.98%
EPS This Year
53.10
from 52.01
Increased by 2.09%
EPS Next Year
63.07
from 53.10
Increased by 18.77%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.